A. Radszuhn

Learn More
The anti-CD25 immunotoxin (IT), RFT5-SMPT-dgA, was used in a phase I dose escalation trial in patients with refractory Hodgkin's lymphoma. The IT was constructed by linking the monoclonal antibody RFT5 via a sterically hindered disulfide linker to deglycosylated ricin-A. All patients in this trial were heavily pretreated with a mean of 5 (range, 2 to 8)(More)
Pancreatic cancer belongs to the group of neoplasms of the greatest mortality. There are taken the trials of surgical treatment, chemotherapy and combine therapy of these two methods. Unfortunately, all of them are not very effective. There are also single reports of using the cytokines (INF tx) in therapy of that disease. As always in that kind of therapy(More)
  • 1